Information for the public
Epcoritamab (Tepkinly) is available on the NHS. It is a possible treatment for relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults. Epcoritamab is stopped after 3 years, or earlier if the lymphoma gets worse.
Relapsed means the cancer has come back after treatment, and refractory means it is not responding well enough to treatment.
Lines of treatment are a sequence of treatments, starting with the best option and moving to alternatives if the first does not work or the condition gets worse. Each line can be a single drug or a combination of drugs.
Systemic treatments are medicines that work throughout the whole body.
If you are not eligible for epcoritamab but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on shared decision making.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS webpage on non-Hodgkin lymphoma may be a good place to find out more.
These organisations can give you advice and support:
- Lymphoma Action, 0808 808 5555
- Follicular Lymphoma Foundation, 0203 417 8583
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
ISBN: 978-1-4731-9328-4
This page was last updated: